Crispr Therapeutics (NASDAQ:CRSP) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Tuesday.
According to Zacks, “CRISPR Therapeutics AG is a gene-editing company. It focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR Therapeutics AG is headquartered in Basel, Switzerland. “
CRSP has been the topic of a number of other reports. Piper Jaffray Companies reiterated an “overweight” rating and set a $53.70 price objective (down from $67.00) on shares of Crispr Therapeutics in a research note on Friday. Oppenheimer reiterated a “hold” rating on shares of Crispr Therapeutics in a research note on Thursday, December 21st. Barclays increased their price objective on shares of Crispr Therapeutics from $29.00 to $59.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 7th. SunTrust Banks upgraded shares of Crispr Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, January 23rd. Finally, BidaskClub upgraded shares of Crispr Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, January 4th. Five investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of $53.53.
Crispr Therapeutics (NASDAQ:CRSP) traded down $0.29 during trading hours on Tuesday, reaching $56.51. 1,460,000 shares of the company were exchanged, compared to its average volume of 1,120,000. The company has a market capitalization of $2,600.00 and a price-to-earnings ratio of -36.22. Crispr Therapeutics has a 1-year low of $13.50 and a 1-year high of $61.24.
In other news, insider Tyler Dylan-Hyde sold 66,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $28.03, for a total value of $1,849,980.00. Following the sale, the insider now directly owns 25,204 shares in the company, valued at approximately $706,468.12. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Thomas Woiwode sold 3,059 shares of the firm’s stock in a transaction that occurred on Friday, December 22nd. The shares were sold at an average price of $20.29, for a total transaction of $62,067.11. Following the completion of the sale, the director now owns 4,959 shares in the company, valued at $100,618.11. The disclosure for this sale can be found here. Insiders have sold 298,850 shares of company stock worth $7,545,365 over the last quarter. Corporate insiders own 39.98% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Wells Fargo & Company MN boosted its stake in shares of Crispr Therapeutics by 17.2% in the 4th quarter. Wells Fargo & Company MN now owns 21,517 shares of the company’s stock valued at $505,000 after purchasing an additional 3,165 shares in the last quarter. ARK Investment Management LLC boosted its stake in shares of Crispr Therapeutics by 22.8% in the 4th quarter. ARK Investment Management LLC now owns 31,388 shares of the company’s stock valued at $737,000 after purchasing an additional 5,833 shares in the last quarter. Creative Planning acquired a new stake in shares of Crispr Therapeutics in the 4th quarter valued at approximately $243,000. Paloma Partners Management Co acquired a new stake in shares of Crispr Therapeutics in the 4th quarter valued at approximately $290,000. Finally, Ark Investment Management LLC acquired a new stake in shares of Crispr Therapeutics in the 2nd quarter valued at approximately $206,000. Institutional investors own 27.29% of the company’s stock.
WARNING: This piece of content was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/03/13/crispr-therapeutics-crsp-stock-rating-upgraded-by-zacks-investment-research.html.
Crispr Therapeutics Company Profile
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Get a free copy of the Zacks research report on Crispr Therapeutics (CRSP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.